Brevan Howard Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Brevan Howard Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$96.5K	Buy	+14,256	New	+$113K	﹤0.01%	2029

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Brevan Howard Capital Management's DMAC Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 14,256 shares worth $96.5K. The stake represents ﹤0.01% of the portfolio and ranks #2029 among its holdings.

98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Brevan Howard Capital Management held 14,256 shares of DiaMedica Therapeutics worth $96.5K as of Q1 2026.
DiaMedica Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
DiaMedica Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2029 holding.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.